Table 1.

Genotype and susceptibility to ciprofloxacin of clinical isolates and their ∆recA mutants.

	Quinolone resistance genotypea
Strain	gyrA1	gyrA2	parC1	parC2	PMQR	STb	SOS response	CIPROFLOXACIN MICc	EUCAST clinical category	Fold change CIPROFLOXACINd	Source of reference
ATCC	-	-	-	-	-	ST73	WT	0.004	S
ATCC ∆recA	-	-	-	-	-	ST73	∆recA	0.001	S	4	Recacha et al. (2017)
FI 4	-	-	-	-	qnrB	ST73	WT	0.5	ATU
FI 4 ∆recA	-	-	-	-	qnrB	ST73	∆recA	0.06	S	8	Machuca et al. (2021)
FI 10	-	-	-	-	qnrB	ST93	WT	0.25	S
FI 10 ∆recA	-	-	-	-	qnrB	ST93	∆recA	0.016	S	15	Machuca et al. (2021)
FI 19	S83L	D87N	S80I	-	qnrS	ST1421	WT	4	R
FI 19 ∆recA	S83L	D87N	S80I	-	qnrS	ST1421	∆recA	2	R	2	Machuca et al. (2021)
FI 20	S83L	-	S80R	-	-	ST131	WT	0.5	ATU
FI 20 ∆recA	S83L	-	S80R	-	-	ST131	∆recA	0.125	S	4	Machuca et al. (2021)
FI 24	S83L	D87N	S80I	E84V	-	ST131	WT	32	R
FI 24 ∆recA	S83L	D87N	S80I	E84V	-	ST131	∆recA	4	R	8	Machuca et al. (2021)

^aMechanisms of quinolone resistance. Resistance-associated mutations located in the GyrA and ParC proteins are defined as resistance mechanisms that alter the target site. PMQR, Plasmid-mediated quinolone resistance genes. ^bSequence-type according to the MLST scheme of the University of Warwick (https://enterobase.warwick.ac.uk/). ^cMIC (mg/L) of agents by microdilution broth. ^dFold reduction in MIC compared with the MIC of clinical isolates (wild-type SOS response). ATU, Area of Technical Uncertainty. S, susceptible. R, resistant.